Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

di Bharmal, Murtuza, Kearney, Mairead, Zheng, Ying, Phatak, Hemant
Pubblicato in Clinicoecon Outcomes Res (2019)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

di Kongnakorn, Thitima, Bharmal, Murtuza, Kearney, Mairead, Phatak, Hemant, Benedict, Agnes, Bhanegaonkar, Abhijeet, Galsky, Matthew
Pubblicato in Clinicoecon Outcomes Res (2019)

Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment...

di Doshi, Gurjyot K, Bhanegaonkar, Abhijeet, Kearney, Mairead, Bharmal, Murtuza, Cislo, Paul, Kim, Ruth, Boyd, Marley, Aguilar, Kathleen M, Phatak, Hemant
Pubblicato in Clinicoecon Outcomes Res (2020)